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Abstract
Introduction Different approaches for disc regeneration
are currently under investigation. Beside gene therapy and
tissue engineering techniques, the application of growth
and differentiation factors own promising potential. Studies
using reduced intervertebral disc models, such as cell or
tissue fragment cultures, have limited validity and show
controversial results depending on the employed experi-
mental model. Therefore, the goal of the current study was
to investigate the effect of BMP-2 and TGF-b3 on inter-
vertebral disc degeneration using an in vitro full-organ
disc/endplate culture system.
Materials and methods Intervertebral rabbit disc explants
were cultured in the presence of 1 lg/ml BMP-2 or TGF-
b3 for 21 days in DMEM/F12 media. Nucleus and annulus
were analyzed for gene expression of collagen type I and II
(Col I/II), aggrecan, collagenases (MMP-1/MMP-13) with
RT-qPCR, histological changes with bone and proteogly-
can-specific staining (von Kossa, toluidine blue) and dif-
ferences in cellularity (DNA) and proteoglycan content
(alcian blue binding assay).
Results The results demonstrate that disc proteoglycan
concentration decreased with time in the TGF-b3 and
BMP-2 groups. In the annulus fibrosus (AF), TGF-b3 and
BMP-2 resulted in an up-regulation of Col I and type II,
and of aggrecan gene expression. In contrast, MMP genes
were inhibited. In the nucleus, the growth factors decreased
gene expression of aggrecan and spontaneous Col I up-
regulation was inhibited by TGF-b3, whereas expression of
Col II was decreased with BMP-2. There was no effect on
expression of MMP-1 and MMP-13 for most sampling
points. However, TGF-b3 and BMP-2 induced ossification
of the AF was demonstrated by histology.
Conclusion It can be concluded that both growth factors,
at the tested concentrations, may not be suitable to regen-
erate the whole intervertebral disc organ but they are
interesting candidates for being injected alone or in com-
bination into a painful intervertebral disc to induce osseous
fusion (spondylodesis).
Keywords Intervertebral disc degeneration  TGF-b3 
BMP-2  In vitro model  Ossification
Introduction
Current treatment of symptomatic intervertebral disc
degeneration consists of either conservative measures, such
as the application of analgesics and physiotherapy or, if not
helpful, surgery is performed [1]. These approaches are not
proven to slow down the degeneration process and conse-
quently relapses or other adverse sequelae of discectomy,
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dynamic stabilization techniques, total disc replacement, or
fusion surgery can be expected [2–6]. Therefore, and as
disc degeneration has a high prevalence and is associated
with major socioeconomic costs, regeneration of the organ
would be desirable [7–9].
Different approaches are currently under investigation:
gene therapy including gene silencing [10, 11], cell-based
tissue engineering strategies including the utilization of
stem cells from different origin [12–15] or the application
of growth factors [10, 16–18].
Growth factors are small signaling proteins, which direct
the development of cells and play a role in embryogenesis,
proliferation and differentiation, tissue homeostasis, immune
response, wound healing and angiogenesis, [19–21]. The
TGF-b (transforming growth factor) superfamily consists
currently of four major subfamilies of dimeric polypeptides:
the TGF-b subfamily (with three isotypes) [22], the DVR
related subfamily including the bone morphogenic proteins
(BMPs) [23, 24], the growth differentiation factor subfamily
(GDF) and the activin/inhibin subfamily.
One of the best described factors is BMP-2, which has
been tested in various in vivo or in vitro intervertebral disc
models. The osteoinductive potential of BMP-2 and pro-
motion of spinal fusion have initially been demonstrated in
animal models [25, 26]. Later, the factor entered clinical
usage for anterior and posterior spondylodesis [27–30].
The capability to reverse intervertebral disc degenera-
tion by up-regulating anabolic factors was described by
Tim Yoon et al. [31] in 2003. In a rat model, BMP-2
increased gene expression of collagen type 2 and aggrecan
in isolated annulus fibrosus (AF) cells. Similar results were
demonstrated in a study employing alginate encapsulated
nucleus pulposus (NP) cells. Here co-cultures with trans-
duced bovine cartilage cells expressing BMP-2 resulted in
cell proliferation and increased accumulation of proteo-
glycans and collagens [32]. However, there is some con-
troversy with regard to the BMP-2 effect between these
positive in vitro results and the later published animal
studies. Animal studies have been conducted to reproduce
the observed in vitro effects, using different kinds of disc
degeneration models, such as the annular puncture method.
In contrast to the former in vitro findings, when injected
into the punctured intervertebral disc, BMP-2 provoked an
acceleration of the degenerative process and even sponta-
neous osseous fusion occurred, as demonstrated on radi-
ography and histology in rabbits [33]. In rabbit disc
puncture models, the injection of transfected disc cells
expressing BMP-2 did not show any regenerative potential
[34] while the intradiscal injection of BMP-7 (OP-1) was
able to restore biomechanical function [35]. Using human
intervertebral disc cells encapsulated in alginate beads,
BMP-7 has been shown to stimulate cell proliferation and
proteoglycan synthesis [36].
Different tissue-specific isoforms of TGF-b with a
homology of 70–80 % and its three receptors are produced
by practically all mammalian cells. TGF-b1 is expressed
primarily by endothelial, connective tissue and hemato-
poietic cells, TGF-b2 by epithelial and neuronal cells and
TGF-b3 mRNA is found mainly in mesenchymal cells
[19, 20].
The gene expression of all three TGF beta isoforms and
type I and type II TGF receptors has been shown to
decrease in cervical intervertebral discs in a senescence-
accelerated mouse model [37]. The potential therapeutic
effect of TGF-b on degenerated intervertebral discs has
been studied in different systems. Gruber et al. [38] stim-
ulated annular cells embedded in alginate or agarose beads
with TGF-b1 and observed an increased cell proliferation
in vitro. In a rabbit adenoviral vector transduction model,
TGF-b1 secretion resulted in an increase of proteoglycan
production in NP cells [39]. Similarly, the injection of
TGF-b1 and GDF-5 into degenerated murine intervertebral
discs resulted in an increase of collagen type II and
aggrecan gene expression [40].
Unlike TGF-b1, the TGF-b3 isotype is currently spar-
sely investigated in disc degeneration or other spinal
models. Steffen et al. [41] demonstrated a massive bone
formation with b-tricalcium phosphate (TCP) cylinders
impregnated with TGF-b3 in an anterior fusion baboon
model. In another study, differences in gene expression
patterns between TGF-b1 and TGF-b3 stimulation of rat
intervertebral discs cells were demonstrated in vitro under
different osmotic conditions [42].
As indicated above, the effects of BMP-2 and TGF-b
strongly depend on the application and the model used. Our
previous studies with full organ rabbit disc cultures have
elicited a spontaneous degeneration of the organ in vitro
over extended culture periods, while basic properties such
as cell viability and differentiation status remained intact.
The model has been validated and shown to be versatile for
studying various pathological conditions [43–45]. The aim
of the study was to investigate if BMP-2 or TGF-b3 are
able to modify the spontaneous degenerative process of
rabbit intervertebral discs in vitro.
Materials and methods
Preparation and culture of intervertebral disc specimens
Intervertebral discs from T7/8 to L6/S1 (12/animal) with
adjacent vertebral endplates were isolated under sterile
conditions within 12 h after sacrifice from six adult female
Burgundy Rabbits (4–5 kg, 4–6 months old) as previously
described [43, 45]. Specimens were assigned to three
groups and cultured for 3 weeks in 6-well plates with
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sampling points at days 1, 3, 14 and 21. Standard media
(9 ml DMEM/F12, 10 % FCS, 25 lg/ml L-ascorbate,
50 lg/ml penicillin, 100 U/ml streptomycin) was supple-
mented with BMP-2 (Medtronic, Inc., Minneapolis, MN,
USA) or TGF-b3 solution (both dissolved in CaCl and
acetate 0.002 %) (Produced by Novartis, kindly donated by
Prof. T. Arvinte, Therapeomics AG, Basel, Switzerland),
both factors with a final concentration of 1 lg/ml. The
control group received CaCl/acetate solution without pro-
tein. Media and growth factors changes were performed
three times/week.
Quantification of proteoglycans
Disc specimens (n = 3/group) were digested overnight with
papain (Sigma, 60 C, 125 lg/ml dissolved in 5 mM L-cys-
teine HCl, 5 mM Na-citrate, 150 mM NaCl, 5 mM EDTA,
pH 6.0). Equal volume of 8 M guanidine HCl was added. For
quantification of proteoglycans, the Alcian blue binding assay
was applied [46] after a two-step precipitation with H2SO4 and
Triton X-100; Alcian blue (2 %, 8GX, Fluka), Triton X-100
(0.25 %, Sigma) and guanidine-HCI (0.5 M) were added to
the samples and left to precipitate overnight at 5 C. Samples
were washed with 40 % DMSO and the precipitate was dis-
sociated with guanidine-HCI (4 M) and propanol (33 %).
Bovine tracheal chondroitin sulphate (Sigma) was used as a
standard. Optical density was determined photometrically
(600 nm). The measures were normalized to DNA.
Quantification of DNA
DNA content was quantified with bisbenzimidol fluores-
cent dye (Hoechst 33258, Sigma). Specimens (n = 3/
group) were prepared as for proteoglycan measurements.
Known concentrations of calf thymus DNA (Sigma) were
used as standard. Samples were diluted 1:50 with tris
(hydroxymethyl)aminomethane (10 mM, Fluka),
Na2EDTA dihydrate (1 mM) and NaCl (100 mM). Fluo-
rescence was detected with Hoefer DyNAQuant (Amer-
sham Biosciences, San Francisco, CA, USA).
Quantitative real time PCR
The disc material (n = 45) was dissected and collected in
RNAlater at the specified sampling point (n = 3/group and
sampling point) and stored at -80 C until further pro-
cessing. For RNA isolation, the sample was covered with
liquid nitrogen and pulverized with RNase free mortar and
pestle. The samples were resuspended with 1 ml of peq-
GOLD TriFast reagent (Peqlab) followed by further
homogenization with a Polytron mixer (Kinematica,
Newark, NJ, USA). RNA was further processed following
the reagent manufacturer’s instructions.
One microgram of total RNA was used for the synthesis
of the cDNA (iScript cDNA Synthesis Kit, BioRad). The
complementary DNA template (5 ll) was mixed with the
RT-PCR mix solution (iQ SYBR Green Supermix, Bio-
Rad), which contained 5 lM specific primers as follows:
House keeping gene: GAPDH Forward: AAGGCCATCA
CCATCTTCCA Reverse: GGATGCGTTGCTGACAAT
CT, Metalloproteinases: MMP-1 Forward: ATACCTGGA
AAACTACTACAATCTG Reverse: TCTTCAGGGTTTC
AGCATCT, MMP-13 Forward: TGCCCCTCCTCAACAG
TAAC Reverse: GAGCCCGCTGCATTCTTCTT Collagen
I Forward: TTCTTGGTGCTGCTGGCATTC Reverse:
GCAATCCGTTGTGTCCCTTTATG, Collagen II Forward:
GACCCCATGCAGTACATG Reverse: GACGGTCTTG
CCCCACTT, Aggrecan Forward: GAGGTCGTGAAA
GGTGT Reverse: GTGTGGATGGGGTACCTGAC.
Quantitative real time RT-PCR (IQ5, Biorad) was con-
ducted with the following settings: denaturation 95 C-10 s
(1 cycle), 40 amplification cycles: 95 C-5 s, 64 C-40 s;
followed by melting curve analysis.
Histology
After tissue fixation in 4 % buffered p-formaldehyde,
specimens were washed, dehydrated and embedded in
PMMA (Sigma). Samples (n = 3) were subsequently cut in
6 lm slices with a microtome (HM360, Microm Interna-
tional AG, Switzerland). Specimens were stained with von
Kossa (Sigma) and counterstained with toluidine blue
(Sigma) dye to demonstrate bone formation as well as
proteoglycan deposits.
Statistics
For statistical analysis the non-parametric ANOVA by
ranks test (Kruskal–Wallis) was used with Statistica 7.1
software (StatSoft, Inc., Tulsa, OK, USA). A significance
value of p \ 0.05 was specified. For PCR experiments a
difference of at least one PCR cycle was considered sig-
nificant, based on serial dilution standard curves in quin-
tuplicates (not shown).
Results
Gene Expression
Collagen type I/II
Collagen type I (Col I) mRNA was not detectable in the NP
in any group until day 7 except one sample in the control
group at a very low concentration (delta CT value of
17.08). In the BMP-2 treated group, Col I gene first
1726 Eur Spine J (2012) 21:1724–1733
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appeared in NP on day seven while it was not expressed in the
controls or in the TGF-b3 group. From day 14 on there was an
increasing expression of Col I in the controls (data not
shown). TGF-b3 strongly inhibited Col I gene expression
from day 14 over the whole period (NP day 14 TGF-b3
0.17 ± 0.05 fold) while BMP-2 did not have any significant
effect on the increasingly expressed Col I (NP day 14 BMP-2
2.02 ± 1.4 fold). On day 21, in the TGF-b3 group, Col I
mRNA was not detectable anymore, while Col I gene
expression further increased in the controls (NP day 21
approx. 1,800 fold compared to day 1 and 4.3 fold compared
to day 14) (data not shown).
In contrast, collagen type II (Col II) gene expression was
decreased by BMP-2 in the beginning from day 1 until day
3 (NP day 1 Col II 0.13 ± 0.19 fold, day 3 0.24 ± 0.13
fold) with no significant difference compared to the
untreated controls in the subsequent course. TGF-b3 did
not have any influence on Col II expression over the entire
observation period in the nucleus (data not shown).
In the AF both BMP-2 and TGF-b3 strongly induced Col I
gene expression on day 1 (AF Col I BMP-2 604 ± 567 fold,
TGF-b3 171 ± 140 fold) with a subsequent decline (Fig. 1a).
There was no qualitative difference between both growth
factors except the kinetics of decline.
Collagen type II gene expression in the annulus was
constantly increased by both growth factors. This however
was statistically significant only for day 14 (AF Col II
BMP-2 5.3 ± 1.2 fold, TGF-b3 17.7 ± 6.2 fold) (Fig. 1b).
Aggrecan
Both, BMP-2 and TGF-b3, had an inhibitory effect on gene
expression of aggrecan in the NP in the first week (NP day
1 BMP-2 0.23 ± 0.02 fold, TGF-b3 0.3 ± 0.002). How-
ever, after 14 days and further after 21 days, BMP-2 and
TGF-b3 did not show any significant difference compared
to the controls (NP day 21 BMP-2 1.3 ± 0.4 fold, TGF-b3
2.1 ± 2.8) (Fig. 2a).
In contrast, BMP-2 and TGF-b3 slightly increased
aggrecan gene expression in the annulus from day 14 until
day 21 (AF BMP-2 5.9 ± 4.8 fold, TGF-b3 9.4 ± 5.9 fold)
(Fig. 2b).
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Fig. 1 Effect of BMP-2 (black bars) and TGF-b3 (white bars) on
gene expression of collagen type I (a) and collagen type II (b) in the
annulus fibrosus. Gene expression of both collagens were increased
with both growth factors. Tissue was analyzed with RT-qPCR at
indicated time points. Data are presented as relative gene expression
to the untreated control and normalized to GAPDH. Values represent
the mean ± SD from triplicates. Asterisk sign. versus ctrl (see
‘‘Method’’ section)
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Fig. 2 Effect of BMP-2 (black bars) and TGF-b3 (white bars) on
gene expression of aggrecan in nucleus (a) and annulus (b) disc
tissue. Gene expression of aggrecan was inhibited by both growth
factors in the nucleus pulposus. In the annulus fibrosus a late minimal
up-regulation of aggrecan could be observed. Nucleus and annulus
tissue was analyzed separately with RT-qPCR at indicated time
points. Data are presented as relative gene expression to the untreated
control and normalized to GAPDH. Values represent the mean ± SD
from triplicates. Asterisk sign. versus ctrl (see ‘‘Method’’ section)
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Collagenases MMP-1, MMP-13
In the annulus, as demonstrated in Fig. 3a, gene expres-
sions of both tested collagenases, MMP-1 and MMP-13,
were markedly suppressed by the growth factors over the
whole observation period (AF maximum day 14 MMP-1
BMP-2 0.13 ± 0.18 fold, TGF-b3 0.007 ± 0.006 fold).
In contrast, in the nucleus, TGF-b3 and BMP-2 did not
have any significant effect on MMP-1 and MMP-13 gene
expression after 21 days (NP MMP-1 BMP-2 2.0 ± 2.3
fold, TGF-b3 2.0 ± 0.6 fold, MMP-13 BMP-2 2.4 ± 0.5
fold, TGF-b3 0.9 ± 0.5 fold). Interestingly TGF-b3 sup-
pressed gene expression of MMP-1 and MMP-13 only at
day 3 in all tested nuclei (NP day 3 MMP-1 0.05 ± 0.04
fold, MMP-13 0.05 ± 0.05 fold). The other samples did
not show any significant difference compared to the
untreated controls (Fig. 3b).
Proteoglycan and DNA measures
The quantification of the glycosaminoglycan content within
the intervertebral disc after 21 days in culture demonstrated
that both factors with BMP-2 or TGF-b3 resulted in a
reduction of proteoglycan content compared to the control
(Fig. 4a, day 21 BMP-2 65.8 ± 21.7 mg GAG/mg DNA,
TGF-b3 57.4 ± 13.3 mg/mg, control 101.01 ± 23.18 mg/
mg, p = 0.125 and p = 0.047).
In contrast the quantification of DNA content did not
show any significant difference between the groups at day
21 (Fig. 4b, day 21 BMP-2 865 ± 100 ng/mg, TGF-b3
950 ± 272 ng/mg, control 859 ± 107 ng/mg, p = 0.94,
p = 0.62).
Histology
Histological analysis demonstrated the ossification of the
AF in the TGF-b3 and the BMP-2 treated groups. Bone
formation was more pronounced with BMP-2 than with
TGF-b3 and first noticed at the anchorage of the annulus
fibers with the endplate. An ossification of the NP was not
observed. Semi-quantitative analysis indicated that pro-
teoglycan contents in the annulus were reduced in the
factor-treated groups (Fig. 5).
Discussion
The objective of the study was to investigate the in vitro
effects of BMP-2 and TGF-b3 on disc degeneration in the
AF and NP compartment, as indicated by changes of ana-
bolic/catabolic gene expression, alterations of proteoglycan
content and histological alterations, in a full organ disc/
endplate rabbit model. Spontaneous degenerative changes
of disc explants with culture time has been observed in a
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Fig. 3 Effect of BMP-2 (black bars) and TGF-b3 (white bars) on
gene expression of collagenases MMP-1 (a, b) and MMP-13 (c, d) in
nucleus (a, c) and annulus disc tissue (b, d). Gene expression of both
collagenases were suppressed with both growth factors in the annulus
fibrosus. In the nucleus pulposus there was no effect of both growth
factors except on day three. Nucleus and annulus tissue was analyzed
separately with RT-qPCR at indicated time points. Data are presented
as relative gene expression to the untreated control and normalized to
GAPDH. Values represent the mean ± SD from triplicates. Asterisk
sign. versus ctrl (see ‘‘Method’’ section)
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previous study, as demonstrated by an up-regulation of col-
lagen I and a decrease of aggrecan and type II collagen gene
transcription in the nucleus and annulus compartment [43].
The hypothesis of the study was that BMP-2 and TGF-b3 may
counteract disc degeneration with anabolic genes being
increasingly expressed and the catabolic pathway blocked.
Both employed growth factors were administered with the
culture media for 21 days in the concentration of 1 lg/ml. We
decided in favour of a comparatively high concentration
because of the potentially limited bio-availability and diffu-
sion capacity of each factor within the relatively large disc
organ. Furthermore, at neutral pH TGF-b3 tends to form
inactive large precipitating aggregates [47]. Risbud et al. [42]
employed the same factor at low concentrations of 10 ng/ml in
a disc organ explant rat model. In other studies using cell
cultures, BMP-2 factor concentrations ranged from 10 to
1,000 ng [31, 48]. However, for in vivo and clinical applica-
tion, BMP-2 was administered in high concentrations such as
1.5 mg/ml as in the rhesus macaque study or 6 mg/cage in an
interbody fusion study in humans [26, 29].
Our results demonstrate that TGF-b3 and BMP-2 show
very similar characteristics in the defined outcome
parameters in the AF and a few divergent responses in the
nucleus pulposus.
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Fig. 4 a, b Effect of BMP-2 and TGF-b3 on GAG and DNA
concentration in full organ disc cultures. A decline of proteoglycan
content was detectable for both growth factors (BMP-2 p = 0.125,
TGF-b3 p = 0.048) after 21 days compared to the control group
which showed an increase of the protein concentration with culture
time. No differences were found for DNA content (BMP-2 p = 0.94,
TGF-b3 p = 0.62). Proteoglycans were quantified using an Alcian
blue-based colorimetric binding assay. DNA amount was determined
with bisbenzimide (Hoechst). GAG content was normalized to DNA
content and DNA was normalized organ weight. Values at indicated
time points represent the mean ± SD from double measures of
triplicates. Asterisk sign. versus ctrl p \ 0.05
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In the gene expression studies with the AF, the quali-
tative results are uniform: both factors strongly continu-
ously increased Col I mRNA at day 1 while Col II
expression was only slightly elevated and aggrecan
expression was mostly unchanged with a slight marginal
late increase at day 21. In parallel the expression of the
catabolic collagenases MMP-1 and MMP-13 were
suppressed.
In the nucleus, however, gene expression of Col I and
type II was differently influenced by both growth factors.
Physiologically, collagen I gene expression is seen only in
the inner annulus but not in the nucleus [49]. With culture
time type I collagen starts to be increasingly expressed in
the NP, which has also been demonstrated in an earlier
study using the same in vitro model [43]. This was
observed by other groups as well [50–52]. TGF-b3 inhib-
ited this gene up-regulation while BMP-2 tended to pro-
mote type I collagen expression in the nucleus similar to
the annulus. In contrast, for Col II, BMP-2 inhibited its
expression while TGF-b3 was ineffective.
The expression of the collagenases MMP-1 and MMP-
13 were unaffected in the nucleus in almost all samples
over the whole culture period, except that TGF-b3 strongly
inhibited both genes exclusively at day three.
The literature regarding gene pattern responses towards
both growth factors in annulus and nucleus tissues is not
consistent. The outer AF mainly consists of type I collagen,
similar to tendon tissue produced by fibrocartilagenous
cells [49, 53]. Yoon et al. [31] could demonstrate that
isolated AF cells in monolayers up-regulated type II
collagen (4.6 fold) and aggrecan (11.5 fold) expression in
response to 1 lg/ml BMP-2. In contrast to our results,
in this study gene expression of type I collagen was
unaffected. Similarly, Li et al., demonstrated an increase of
aggrecan and type II collagen gene expression employing a
substance concentration of 200 ng/ml BMP-2 in cell cul-
ture media on rat annulus cells. Again type I collagen
mRNA concentration did not respond to the growth factor
application [48]. In contrast, in the cell culture studies by
Kuh et al. [54] using AF cells BMP-2 stimulated the
expression of both collagen types.
In the annulus, both applied growth factors induced a
strong gene response of Col I expression in the first week
and secondarily, when collagen I declined, an increase of
Col II gene and to a smaller extent aggrecan in the second
and third week.
In the NP we found that BMP-2 tended to increase type I
collagen expression. This effect has also been demon-
strated using 3D alginate bead cultures from isolated
human nucleus (NP)/transition zone cells by Kim et al.
[55]. Beside type I collagen, the expression of aggrecan
and type II collagen but not of the osteocalcin gene were
increased using various concentrations of BMP-2 (up to
2 lg/ml). This finding was confirmed by Gilbertson et al.
[56] using human NP monolayer cultures and by Zhang
et al. [57] with the quantification of the gene products
(collagen and proteoglycan content). In contrast to this, in
the current study we observed a down regulation of
aggrecan and type II collagen gene expression in the first
week in the NP with BMP-2. Conflicting Col I, Col II and
aggrecan gene pattern in annulus and nucleus samples may
be due to the organ culture characteristics, with resident
growth factors embedded in the retained physiological
extracellular matrix and the present cell-matrix interac-
tion and/or to the high concentration of growth factors
employed.
A B C
Fig. 5 Effect of BMP-2 and TGF-b3 on disc histology. Disc
specimens were embedded into PMMA and histological section were
stained with von Kossa (bone specific, black stain) and toluidine blue
(GAG specific, blue stain). Unlike the untreated control (left side) an
ossification of the annulus (arrows) with a decrease of GAG
concentration could be observed with BMP-2 (right side) and to a
lesser extent with TGF-b3 (middle) after 21 days (12.5x)
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The effects of most growth and differentiation factors are
studied predominantly in the context of cell differentiation
using undifferentiated stem cells of different origin or using
isolated organ cells like cartilage/connective tissue cells to
study gene expression and matrix production under differ-
ent environmental conditions such as in scaffolds for tissue
engineering [58]. Consequently, data on the effects of the
TGF beta isoforms on differentiated organs such as the
intervertebral disc are sparse. Haberstroh et al. [59] studied
human cell cultures using isolated NP cells from surgical
specimens obtained from routine microdiscectomy. TGF-
b3 (10 ng/ml) resulted in gene up-regulation of collagen
types I, II, III, IX and aggrecan as well as matrix production.
In NP cell cultures from volunteers, which were stimulated
with platelet-rich plasma and 1 ng/ml TGF-b1, type II
collagen, aggrecan as well as sox 9 were significantly up-
regulated as demonstrated with real time PCR [60]. In a
murine model encompassing the induction of disc degen-
eration with static compression 200 ng/ml TGF-b1 caused
an expansion of fibrocartilage cells into the nucleus which
were positive for Col II and aggrecan mRNA as demon-
strated by in situ hybridization [40].
The histological results indicated a decrease of proteo-
glycan content in the annulus which can be explained by a
slow loss via diffusion into the media and/or activation of
gelatinases with time, which was not compensated by
synthesis. The last finding could be confirmed by our
measures of proteoglycan content, which, however, were
taken from the entire intervertebral disc. Here a decrease of
proteoglycan amount could be observed in both factor-
treated groups after 21 days with a significance level of
p \ 0.05 only for TGF-b3. The decrease of the extracel-
lular matrix macromolecule is in accordance with our PCR
results, which demonstrated that aggrecan gene expression
was down-regulated in the nucleus pulposus, the major
localization of this protein and a mostly unchanged gene
expression in the AF.
Histological analysis using von Kossa stain, further-
more, clearly demonstrated that BMP-2 and TGF-b3
induced ossification of the AF, which was pronounced at
the anchorage of the annulus fibers with the vertebral
endplate. Ossification encompassed the mineralization of
the annular fibers with deposition of calcium salts. Similar
to annulus tissue, a major compound of the organic bone
matrix is Col I.
Several different spinal pathologies involve dystrophic
ossification of the annulus and/or the longitudinal ligaments
such as ankylosing spondylitis, ossification of the posterior
longitudinal ligament (OPLL), diffuse idiopathic skeletal
hyperostosis (DISH) or fibrodysplasia ossificans progressi-
va (FOP) [61, 62]. The latter is caused by a single nucleo-
tide missense mutation of the bone morphogenic protein
type I receptor (ACVR1/ALK2) [63]. Experimentally-
induced ossification of the intervertebral discs by injection
of BMP-2 (1 mg/ml) with or without coral was demon-
strated by Huang et al. [33] in an annular stab incision rabbit
model. Similarly, in a baboon model when using a TGF-b3/
beta-TCP compound to fill vertebral bone defects, a mas-
sive regional bone formation around the bone implicating
soft tissue ossification could be observed [41].
Taken together, the data demonstrated that the admin-
istration of BMP-2 or TGF-b3 to the intervertebral disc
with its naturally retained microenvironment caused ossi-
fication of the AF within 3 weeks with an increased Col I
gene expression (and to a lesser extent also Col II
expression) and inhibition of catabolic collagenases. This
may be regarded as an osseous anabolic process but
involves changes of the original disc architecture and is
commonly observed in late state disc degeneration. How-
ever, this conclusion must be qualified by our selection of a
relatively high, yet clinically relevant, concentration of
1 lg/ml in the culture media.
In the nucleus pulposus, anabolic genes such as aggre-
can and Col II were inhibited by BMP-2 and catabolic
collagenases were practically unaffected by both factors.
Interestingly, unlike in the annulus compartment, TGF-b3
inhibited the expression of Col I. Collagen type I expres-
sion in the NP is an indicator of disc degeneration. The
relevance of these findings remains unclear as well as a
possible impact on an eventual later ossification of the
nucleus, which was so far not observed. This, however,
may be a question of culture time. The employed protein
concentration, intra-organ concentration differences and
the way of growth factor administration are key points and
have to be considered cautiously. Although both factors at
the tested concentrations may not be suitable to regenerate
the whole intervertebral disc organ, they are interesting
candidates for being injected alone or in combination into a
painful intervertebral disc to induce osseous fusion
(spondylodesis). Whether the in vivo application of TGF-
b3 would be devoid of MMP-2 typical adverse effects,
which have been lately reviewed by Carragee [64] such as
ectopic bone formation [65], radiculopathy [66], wound
complications [67], implant migration [68] and even car-
cinogenesis [64] as well as the observed divergent effects
of both factors and the analysis of the involved bone-
related genes need further investigations.
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